For the quarter ended June 2026, Solventum (SOLV Quick QuoteSOLV - Free Report) reported revenue of $2.21 billion, up 2.2% over the same period last year. EPS came in at $2.55, compared to $1.69 in the year-ago quarter.

The reported revenue represents a surprise of +2.03% over the Zacks Consensus Estimate of $2.17 billion. With the consensus EPS estimate being $1.91, the EPS surprise was +33.51%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Solventum performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Sales- MedSurg: $1.37 billion compared to the $1.34 billion average estimate based on four analysts. The reported number represents a change of +12.6% year over year.
• Net Sales- Dental Solutions: $396 million compared to the $384.42 million average estimate based on four analysts. The reported number represents a change of +17.2% year over year.
• Net Sales- Health Information Systems: $354 million versus $354 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4.4% change.
• All Other: $87 million versus the three-analyst average estimate of $76.33 million.

View all Key Company Metrics for Solventum here>>>

Shares of Solventum have returned +15.3% over the past month versus the Zacks S&P 500 composite's +3.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.